The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Five-year outcomes of perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (the NEONAX trial): A randomized phase II trial of the AIO pancreatic cancer group.
 
Thomas Ettrich
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Ipsen; Lilly; Merck Serono; MSD; Pierre Fabre; Roche; Sanofi; SERVIER; Takeda
Research Funding - Baxalta/Shire; Lilly (Inst)
Travel, Accommodations, Expenses - Ipsen; Lilly
 
Waldemar Uhl
No Relationships to Disclose
 
Marko Kornmann
No Relationships to Disclose
 
Hana Algül
No Relationships to Disclose
 
Helmut Friess
No Relationships to Disclose
 
Alexander Koenig
Honoraria - Ipsen; Pierre Fabre
Consulting or Advisory Role - Roche
 
Thomas Gress
No Relationships to Disclose
 
Eike Gallmeier
No Relationships to Disclose
 
Manfred Lutz
Research Funding - SERVIER (Inst)
 
Kai Wille
No Relationships to Disclose
 
Carl Schimanski
Employment - Merck KGaA (I)
Research Funding - Merck KGaA (Inst)
 
Volker Kunzmann
Honoraria - BMS GmbH & Co. KG
 
Dirk Waldschmidt
No Relationships to Disclose
 
Severin Daum
No Relationships to Disclose
 
Swantje Held
No Relationships to Disclose
 
Lukas Perkhofer
Consulting or Advisory Role - AstraZeneca; SERVIER
Expert Testimony - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca
 
Jasmin Schuhbaur
No Relationships to Disclose
 
Margaret Tempero
Honoraria - CPRIT
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Pfizer; ElmediX; Geron; Global Bio Access Fund; Guardant Health; Immodulon Therapeutics; IPSEN Biopharma, Inc.; Merus NV; Mirati Therapeutics; PEPTOMYC; Regeneron; RenovoRx
Travel, Accommodations, Expenses - Abbvie; Bristol-Myers Squibb
 
Anke Reinacher-Schick
Honoraria - MCI Group; MSD; Pierre Fabre; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Aurikamed; Boehringer Ingelheim; Daiichi Sankyo; MCI Deutschland; Pierre Fabre; Roche; Servier
Research Funding - AIO-Studien (Inst); BioNTech (Inst); Genentech (Inst); Georg-August-Universität Göttingen (UMG) (Inst); Rafael Pharmaceuticals (Inst); Roche (Inst)
Travel, Accommodations, Expenses - MCI Deutschland; MSD; Pierre Fabre; Roche
 
Thomas Seufferlein
Honoraria - AstraZeneca; BMS GmbH & Co. KG; Falk Foundation; MSD Oncology; Pierre Fabre; SERVIER; Takeda
Consulting or Advisory Role - BioNTech SE; Boehringer Ingelheim; Cantargia AB; Mirati Therapeutics; Olympus Medical Systems; Pierre Fabre; Scandion Oncology; SERVIER
Research Funding - Lilly/ImClone (Inst)
Travel, Accommodations, Expenses - Takeda